Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N M Barth

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trialR O Dillman, R K Oldham, K W Tauer, et al.
Neuro-Oncology|April 18, 2001
Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade gliomaR O Dillman, W M Shea, D F Tai, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanomaR O Dillman, S K Nayak, N M Barth, et al.
Critical Reviews in Oncology/Hematology|June 22, 2001
Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanomaR O Dillman, C DeLeon, L D Beutel, et al.
Cancer|July 1, 1991
Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trialR O Dillman, R K Oldham, N M Barth, et al.
Molecular Biotherapy|June 1, 1991
Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group TrialR K Oldham, R O Dillman, J R Yannelli, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trialR O Dillman, R K Oldham, K W Tauer, et al.
Neuro-Oncology|April 18, 2001
Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade gliomaR O Dillman, W M Shea, D F Tai, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanomaR O Dillman, S K Nayak, N M Barth, et al.
Critical Reviews in Oncology/Hematology|June 22, 2001
Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanomaR O Dillman, C DeLeon, L D Beutel, et al.
Cancer|July 1, 1991
Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trialR O Dillman, R K Oldham, N M Barth, et al.
Molecular Biotherapy|June 1, 1991
Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group TrialR K Oldham, R O Dillman, J R Yannelli, et al.
Pageof 2